US2023030428A1PendingUtilityA1

Stem cell composition

77
Assignee: MESOBLAST INT SARLPriority: Apr 7, 2014Filed: Mar 9, 2022Published: Feb 2, 2023
Est. expiryApr 7, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Silviu ItescuPaul Simmons
C12N 2501/2301A61K 35/28C12N 2500/38A61P 9/10C12N 2501/25C12N 5/0663C12N 5/0662C12N 2501/39A61P 7/02C12N 2501/135A61P 43/00A61P 9/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.

Claims

exact text as granted — not AI-modified
1 . A composition comprising genetically unmodified stem cells wherein said genetically unmodified stem cells express angiopoietin-1 (Ang1) and Vascular Endothelial Growth Factor (VEGF) at a ratio of Ang1:VEGF between 2:1 and 30:1. 
     
     
         2 . The composition of  claim 1  wherein said stem cells express Ang1 in an amount of at least 0.5 μg/10 6  cells. 
     
     
         3 . The composition of  claim 1  wherein said stem cells express Ang1 in an amount of at least 0.7 μg/10 6  cells. 
     
     
         4 . (canceled) 
     
     
         5 . The composition of  claim 1 , wherein said stem cells express Vascular Endothelial Growth Factor (VEGF) in an amount less than about 0.05 μg/10 6  cells. 
     
     
         6 - 7 . (canceled) 
     
     
         8 . The composition of  claim 1 , wherein said stem cells express Ang1:VEGF at a ratio between 2:1 and 20:1. 
     
     
         9 - 12 . (canceled) 
     
     
         13 . The composition of  claim 1 , wherein said stem cells are mesenchymal stem cells. 
     
     
         14 . The composition of  claim 13  wherein said stem cells are mesenchymal precursor cells. 
     
     
         15 . (canceled) 
     
     
         16 . An in vitro method for inducing therapeutic Ang1:VEGF expression in stem cells, the method comprising: culturing a population of stem cells in a cell culture media, wherein the cell culture media
 contains a short acting L-ascorbic acid derivative but does not contain a substantial amount of a long acting L-ascorbic acid derivative; and/or   is supplemented with less than 10% v/v fetal calf serum (FCS); and/or   is supplemented with non-fetal serum.   
     
     
         17 - 33 . (canceled) 
     
     
         34 . A method for obtaining genetically unmodified stem cells suitable for use in promoting vascularisation and/or angiogenesis, comprising:
 obtaining at least one cell population including stem cells from at least one donor;   culturing the stem cells;   determining the amount of Ang1 and VEGF expressed by the stem cells in each of said at least one cell population(s); and   selecting stem cells which express Ang1:VEGF in an amount of at least 0.1 μg/10 6  cells.   
     
     
         35 . The method of  claim 34  which further comprises:
 determining the amount of VEGF expressed by the stem cells in each of said at least one cell population(s); and 
 selecting stem cells which express Ang1:VEGF at a ratio between 2:1 and 30:1. 
 
     
     
         36 - 40 . (canceled) 
     
     
         41 . A method for promoting vascularisation and/or angiogenesis in a subject, the method comprising administering the composition of  claim 1  to the subject. 
     
     
         42 . A method for treating a condition in which increased Ang1 expression is desirable in a subject, the method comprising administering to the subject the composition of  claim 1 . 
     
     
         43 - 46 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.